Navigation Links
Calvert Holdings Announces Executive Changes for Calvert Research
Date:4/9/2010

Calvert Holdings, Inc. announced today the appointment of Michael A. Recny, Ph.D. as President of Calvert Research, LLC. Mr. Sam Tetlow, MBA will assume the new role of Vice President of Business Development.

Cary, NC (PRWEB) April 9, 2010 -- Calvert Holdings, Inc. announced today a restructuring of executive responsibilities within in its Calvert Research, LLC business unit, effective April 1, 2010.


Michael A. Recny, Ph.D. has been appointed as President of Calvert Research, LLC, assuming the position currently held by Russ McLauchlan, Chairman & Chief Executive Officer of Calvert Holdings, Inc.

"Michael and I have now worked together for several years, and I have come to appreciate that he is a highly competent individual who has a keen ability to balance his skills as an experienced scientist and successful drug developer with appropriate business insight and discipline" said Russ McLauchlan. "Together we formed Calvert BioCapital, a new venture fund that would focus on acquiring and developing early stage drug candidates licensed from major universities. While fundraising for the venture fund has now been terminated, we continue to believe the fundamental strategy we set is sound and viable. Our history of working with University technology transfer offices and young biopharmaceutical companies to develop and then identify clinical development partnerships gives us confidence our business model is sustainable. The changes in management responsibilities are designed to accelerate the pace of our portfolio development."

Dr. Recny will be responsible for building an internal portfolio of clinical stage drug candidates within Calvert Research utilizing the same core elements of the investment strategy that he and Russ McLauchlan formulated in 2007.

"I am very pleased to assume this new leadership role within Calvert Research," said Dr. Recny. "We will continue to focus on implementing our capital efficient, virtual drug development model to create clinical stage assets that will be attractive acquisitions candidates for pharmaceutical and biotechnology partners. Our current drug candidate consists of a novel, patented compound we licensed from Tulane University in 2009 for the potential treatment of the wet form of age-related macular degeneration that is currently being evaluated in preclinical studies, and we look forward to expanding our portfolio with additional assets in the near future."

Sam C. Tetlow, MBA will assume a new role as Vice President of Business Development for Calvert Research. In this position, Mr. Tetlow will be instrumental in setting the strategic direction of the compounds and technologies housed within the Calvert Research portfolio while cultivating relationships with corporate partners interested in collaborating and acquiring rights to portfolio technologies as they advance toward human clinical trials.

"Sam first joined Calvert BioCapital shortly after we formed the fund, and we quickly learned that he improved our ability to interface with the investment community with his operational and strong investment experience," said Russ McLauchlan. "In his new role within Calvert Research, Sam will be instrumental in helping to execute our business model, as well as contributing to other important business initiatives within Calvert Holdings, Inc."

Andy Burch, Vice President of Calvert Research, will continue to lead the direct involvement of Calvert Research with University Technology Transfer offices and will add to his role as President of Carolina Securities LLC, a wholly owned business unit of Calvert Holdings, Inc. Mr. Burch will also assume additional responsibilities for new business initiatives within Calvert Holdings, Inc. "Andy is a valued member of the Calvert organization and we look to him to drive the implementation of many initiatives we have put into our longer term strategic plan," said Mr. McLauchlan. "We know that Andy has been key to our success in multiple sectors of our businesses, and we want to deploy his efforts across several other areas of our company."

About Calvert Holdings, Inc.
Formed in 1996, Calvert Holdings, Inc. is a privately held company consisting of a diverse portfolio of companies including the following: Calvert Laboratories, Calvert Research, Calvert Creative, Carolina Securities, and Calvert Café & Catering.

Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.

###

Read the full story at http://www.prweb.com/releases/2010/04/prweb3851054.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Dr. Jay Calvert MD Announces Details on New Patent-Protected Investigational Breast Implants
2. Concord Medical Services Holdings Limited Announces Pricing of Initial Public Offering on the New York Stock Exchange
3. TeamHealth Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2009 Earnings Release Date and Conference Call
4. XenaCare Holdings Announces Expansion of National Advertising Campaign for its Over-the-Counter (OTC) Pain Reliever, Cobroxin, as Retailer Commitments Grow
5. Equinox Holdings, Inc. Commences $400 Million Private Debt Offering
6. American Diversified Holdings Corporation Announces Appointment of Independent Director to the Board of the Company
7. XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation
8. American Diversified Holdings Corporation Announces Stem Cell Patent Acquisition Program
9. Applied Technology Holdings, Inc. Forms First New Subsidiary Called MVP Sports Technologies, Inc.
10. syncreon Acquires NAL Worldwide Holdings Inc.
11. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Calvert Holdings Announces Executive Changes for Calvert Research 
(Date:10/13/2017)... PITTSBURGH, Pa. (PRWEB) , ... October 13, 2017 , ... ... the dark poses a problem. Fortunately, an inventor from Austin, Texas, has identified a ... access to medication in darkness or restricted lighting. As such, it eliminates the need ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... York, NY (PRWEB) , ... October 13, 2017 , ... ... influential people in business to advocate for action towards gender equality at their inaugural ... views from around the globe, and reached a social audience of over 3 million. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/22/2017)... , Sept. 22, 2017  As the latest ... Senators Bill Cassidy (R-LA) and Lindsey ... notes that the medical device industry is in an ... device tax, the 2.3% excise tax on medical device ... they also want covered patients, increased visits and hospital ...
Breaking Medicine Technology: